Revance Therapeutics, Inc.

Ownership Transactions Reported by 16 Insiders

Location
1222 Demonbreun Street, Suite 2000, Nashville, TN

There are no Buy or Sell transactions made by insiders since 11/20/2024

Revance Therapeutics, Inc. executives and other stock owners filed with the SEC include:

Name Relationship Holdings Value Past Year Net Change Change % Report Date
Aubrey Rankin Director $4.26M Mar 15, 2022
Abhay Joshi COO, President of R&D $902K Mar 15, 2022
Dustin S. Sjuts President $845K Mar 15, 2024
Philip J. Vickers Director $222K May 4, 2022
Olivia C. Ware Director $0 Feb 4, 2025
Julian S. Gangolli Director $0 Feb 4, 2025
Jill Beraud Director $0 Feb 4, 2025
Carey OConnor Kolaja Director $0 Feb 4, 2025
Mark J. Foley President & CEO, Director $0 Feb 4, 2025
Dwight Moxie Clo & Gc $0 Feb 4, 2025
Tobin Schilke Cfo $0 Feb 4, 2025
David Hollander CMO & Global Therapeutics Lead $0 Feb 4, 2025
Vlad Coric Director $0 Feb 4, 2025
Erica Jordan Chief Commercial Officer $0 Feb 4, 2025
Chris Nolet Director $0 Feb 4, 2025
Angus C. Russell Director $0 Feb 4, 2025

Recent Insider Transactions by Companies or Individuals for Revance Therapeutics, Inc.

Insider Symbol Class Transaction % Value $ * Price $ Shares Shares Owned Date Ownership
* An asterisk sign (*) next to the price indicates that the price is likely invalid.